Company / R&D per Share
REGENXBIO Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.61
FY2025
5-year range
$3.31 / $5.66
FY2021-FY2025
Trend
-2.7%
vs FY2024
Sector context
#41 of 208
Health Care
What the data says
REGENXBIO Inc.'s r&d per share of $4.61 is higher than 80% of companies in the Health Care sector (FY2025). R&D per Share has declined for 3 consecutive years, from $5.66 in FY2022 to $4.61 in FY2025.
Based on SEC 10-K filings.
4.61 in FY2025 with a 5-year CAGR of +15.2%. Top quartile in the Health Care sector.
Declined from $5.36 to $4.61 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -6.6%
- 5-Year CAGR
- +15.2%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 208This company $4.61 Sector average $12.19
▼
-62.2% below sector average
Key checks
Key Insights
- REGENXBIO Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 2.7% year-over-year.
- Ranks #41 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.61 | -2.7% |
| FY2024 | $4.73 | -11.7% |
| FY2023 | $5.36 | -5.2% |
| FY2022 | $5.66 | +70.8% |
| FY2021 | $3.31 | +46.2% |
| FY2020 | $2.27 | +43.1% |
| FY2019 | $1.58 | -40.9% |
| FY2018 | $2.68 | +24.0% |
| FY2017 | $2.16 | +1046.3% |
| FY2016 | $0.19 | -90.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026